These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results. Srour SA; Li S; Popat UR; Qazilbash MH; Lozano-Cerrada S; Maadani F; Alousi A; Kebriaei P; Anderlini P; Nieto Y; Jones R; Shpall E; Champlin RE; Hosing C Br J Haematol; 2017 Aug; 178(4):561-570. PubMed ID: 28485023 [TBL] [Abstract][Full Text] [Related]
44. Results of autologous transplantation in lymphoma are not improved by increasing the dose of etoposide in the BEAM regimen: a single-centre sequential-cohort study. Martín A; Caballero MD; Pérez-Simón JA; López-Holgado N; Mateos MV; Cañizo MC; Miguel JF Bone Marrow Transplant; 2004 Oct; 34(8):675-82. PubMed ID: 15334049 [TBL] [Abstract][Full Text] [Related]
46. Radium beam therapy. WOOD CA J Fac Radiol; 1951 Oct; 3(2):79-94. PubMed ID: 24541740 [No Abstract] [Full Text] [Related]
47. A new roentgen-ray beam director for precision radiation therapy. ROSWIT B Am J Roentgenol Radium Ther; 1951 Jan; 65(1):115-8. PubMed ID: 14799673 [No Abstract] [Full Text] [Related]
48. Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA). You B; Salles G; Bachy E; Casasnovas O; Tilly H; Ribrag V; Sebban C; Hénin E; Guitton J; Tod M; Freyer G Cancer Chemother Pharmacol; 2015 Nov; 76(5):939-48. PubMed ID: 26391155 [TBL] [Abstract][Full Text] [Related]
49. [Lenalidomide induced therapeutic response in a patient with aggressive multi-system Langerhans cell histiocytosis resistant to 2-chloro-deoxyadenosine and early relapsing after high-dose BEAM chemotherapy with autologous peripheral blood stem cell transplantation]. Adam Z; Rehák Z; Koukalová R; Szturz P; Krejčí M; Pour L; Zahradová L; Moulis M; Kodet R; Nebeský T; Brejcha M; Adamová Z; Hájek R; Mayer J Vnitr Lek; 2012 Jan; 58(1):62-71. PubMed ID: 22448704 [TBL] [Abstract][Full Text] [Related]
50. Acute myocardial ischemia after high-dose therapy with BEAM regimen. Genet P; Pulik M; Gallet B; Lionnet F; Jondeau K; Touahri T; Laribi K Bone Marrow Transplant; 2002 Aug; 30(4):253-4. PubMed ID: 12203142 [TBL] [Abstract][Full Text] [Related]
51. Radium beam therapy at the Western Infirmary of Glasgow, 1938-48. CHARTERIS AA J Fac Radiol; 1951 Oct; 3(2):95-110. PubMed ID: 24541741 [No Abstract] [Full Text] [Related]
52. Autologous stem-cell transplantation for non-Hodgkin's lymphomas: the role of graft purging and radiotherapy posttransplantation--results of a retrospective analysis on 120 patients autografted in a single institution. Fouillard L; Laporte JP; Labopin M; Lesage S; Isnard F; Douay L; Lopez M; Aoudjhane M; Zunic P; Cheron N; Stachowiak J; Lemonnier MP; Andreu G; Belkacemi Y; Noël-Walter MP; Morel P; Fenaux P; Jouet JP; Bauters F; Najman A; Gorin NC J Clin Oncol; 1998 Aug; 16(8):2803-16. PubMed ID: 9704733 [TBL] [Abstract][Full Text] [Related]
53. Construction of a dual beam heated infrared cell. NEU JT J Opt Soc Am; 1953 Jun; 43(6):520-1. PubMed ID: 13070115 [No Abstract] [Full Text] [Related]
54. A long-term follow-up of 33 patients with non-Hodgkin's lymphoma who received the BEAM high-dose intensification regimen with cytokine support only and no transplant. Laporte JP; Yeshurun M; Fouillard L; Labopin M; Cailliot C; Lesage S; Isnard F; Najman A; Gorin NC Leukemia; 2004 Oct; 18(10):1717-21. PubMed ID: 15295607 [TBL] [Abstract][Full Text] [Related]
55. Phase I study for poor-prognosis lymphoma: augmentation of the "BEAM" regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation--a preliminary report. Phillips GL; Abboud CN; Bernstein SH; Friedberg JW; Ifthikharuddin JJ; Lancet JE; Liesveld JL; Spreng E; Johnson V; Chapman M; Vesole DH Semin Oncol; 2004 Dec; 31(6 Suppl 18):59-61. PubMed ID: 15726525 [TBL] [Abstract][Full Text] [Related]
56. Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma. Costa LJ; Micallef IN; Inwards DJ; Johnston PB; Porrata LF; Litzow MR; Ansell SM Br J Haematol; 2008 Oct; 143(2):268-73. PubMed ID: 18699848 [TBL] [Abstract][Full Text] [Related]
57. Facilities for handling and storage of medical radiation sources in a large hospital unit. BAILY NA Am J Roentgenol Radium Ther Nucl Med; 1960 Mar; 83():462-4. PubMed ID: 13795883 [No Abstract] [Full Text] [Related]
58. Treatment of lymphoma relapses after allogeneic hematopoietic stem cell transplantation with intensive chemotherapy followed by infusion of hematopoietic stem cell from the original donor. Au WY; Lie AK; Siu LL; Chan EC; Ooi GC; Leung AY; Liang R; Kwong YL Ann Hematol; 2003 Sep; 82(9):548-51. PubMed ID: 14504811 [TBL] [Abstract][Full Text] [Related]
59. High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single centre 10-year experience. Krasulová E; Trneny M; Kozák T; Vacková B; Pohlreich D; Kemlink D; Kobylka P; Kovárová I; Lhotáková P; Havrdová E Mult Scler; 2010 Jun; 16(6):685-93. PubMed ID: 20350962 [TBL] [Abstract][Full Text] [Related]
60. Influence of beam trypsin inhibitors on thromboplastic properties of trypsin and hypochlorite-treated trypsin. BOWMAN DE Proc Soc Exp Biol Med; 1954 Jul; 86(3):491-4. PubMed ID: 13194700 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]